Dyck Peter James
Peripheral Neuropathy Research Laboratory, Mayo Clinic, Rochester, MN, USA.
Handb Clin Neurol. 2014;126:335-8. doi: 10.1016/B978-0-444-53480-4.00024-2.
This chapter outlines: (1) the reasons why epidemiologic surveys and randomized controlled clinical trials (RCTs) of diabetic polyneuropathy (DPN) are difficult and expensive, and often poorly done, (2) primary and secondary neuropathy end points, (3) single versus composite neuropathic end points, (4) adequate reference values from study of population representative cohorts, and (5) the issue of clinical proficiency.
（1）糖尿病性多发性神经病变（DPN）的流行病学调查和随机对照临床试验（RCT）困难且昂贵，且往往执行不佳的原因；（2）原发性和继发性神经病变终点；（3）单一与复合神经病变终点；（4）来自具有人群代表性队列研究的充分参考值；以及（5）临床熟练度问题。
